A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma

CONCLUSIONS: Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.PMID:36971773 | DOI:10.1158/1078-0432.CCR-22-3911

Source: Clinical Cancer Research - March 27, 2023 Category: Cancer & Oncology Authors: Ciara M Kelly Li-Xuan Qin Karissa A Whiting Allison L Richards Viswatej Avutu Jason E Chan Ping Chi Mark A Dickson Mrinal M Gounder Mary Louise Keohan Sujana Movva Benjamin A Nacev Evan Rosenbaum Travis Adamson Samuel Singer Edmund K Bartlett Aimee M Crag Source Type: research